Value of whole-body FDG PET in management of lung cancer
| Autor: | Kotaro Higashi, Yoshimichi Ueda, Manabu Oguchi, Ryosuke Ikeda, Hisao Tonami, Itaru Yamamoto, Ichiro Matsunari, Jianfei Guo |
|---|---|
| Rok vydání: | 2003 |
| Předmět: |
Pathology
medicine.medical_specialty Lung Neoplasms Disease Malignancy Sensitivity and Specificity Whole-Body Counting Fluorodeoxyglucose F18 medicine Carcinoma Humans Radiology Nuclear Medicine and imaging In patient Lung cancer Neoplasm Staging medicine.diagnostic_test business.industry Radiotherapy Planning Computer-Assisted Reproducibility of Results Solitary Pulmonary Nodule General Medicine Pet imaging medicine.disease Drug Therapy Computer-Assisted Positron emission tomography Radiology Neoplasm Recurrence Local Radiopharmaceuticals Whole body business Tomography Emission-Computed |
| Zdroj: | Annals of Nuclear Medicine. 17:1-14 |
| ISSN: | 1864-6433 0914-7187 |
| DOI: | 10.1007/bf02988253 |
| Popis: | 18F-fluorodeoxyglucose (FDG) PET imaging provides physiologic and metabolic information that characterizes lesions that are indeterminate by CT. FDG PET imaging is sensitive to the detection of lung cancer in patients who have indeterminate lesions on CT, whereas low grade malignancy such as bronchioloalveolar carcinoma and carcinoid may be negative on FDG PET. The specificity of PET imaging is less than its sensitivity because some inflammatory processes, such as active granulomatous infections, avidly accumulate FDG. This possibility should be kept in mind in the analysis of PET studies of glucose metabolism aimed at differentiating malignant from benign solitary pulmonary nodules. FDG uptake is considered to be a good marker of cell differentiation, proliferative potential, aggressiveness, and the grade of malignancy in patients with lung cancer. FDG PET accurately stages the distribution of lung cancer. Several studies have documented the increased accuracy of PET compared with CT in the evaluation of the hilar and mediastinal lymphnode status in patients with lung cancer. Whole-body PET studies detect metastatic disease that is unsuspected by conventional imaging. Management changes have been reported in up to 41% of patients on the basis of the results of whole-body studies. Whole-body FDG PET is also useful for the detection of recurrence. Several studies have indicated that the degree of FDG uptake in primary lung cancer can be used as an independent prognostic factor. Thus, whole-body FDG PET is clinically very useful in the management of lung cancer. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink